| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antirheumatic Agents | 165 | 2023 | 1339 | 17.400 |
Why?
|
| Arthritis, Rheumatoid | 288 | 2024 | 3712 | 17.130 |
Why?
|
| Methotrexate | 100 | 2023 | 1727 | 9.480 |
Why?
|
| Oxazines | 9 | 2018 | 298 | 2.560 |
Why?
|
| Receptors, Tumor Necrosis Factor | 22 | 2015 | 595 | 2.360 |
Why?
|
| Tumor Necrosis Factor-alpha | 36 | 2018 | 4420 | 1.900 |
Why?
|
| Antibodies, Monoclonal | 39 | 2018 | 9274 | 1.810 |
Why?
|
| Biological Products | 12 | 2023 | 860 | 1.530 |
Why?
|
| Rheumatic Diseases | 18 | 2022 | 592 | 1.490 |
Why?
|
| Double-Blind Method | 52 | 2023 | 12026 | 1.460 |
Why?
|
| Severity of Illness Index | 77 | 2024 | 15540 | 1.460 |
Why?
|
| Drug Therapy, Combination | 45 | 2023 | 6489 | 1.360 |
Why?
|
| Immunoglobulin G | 24 | 2015 | 4560 | 1.310 |
Why?
|
| Pyridines | 10 | 2018 | 2825 | 1.290 |
Why?
|
| Immunoconjugates | 10 | 2013 | 901 | 1.180 |
Why?
|
| Rheumatology | 16 | 2021 | 576 | 1.160 |
Why?
|
| Rheumatoid Factor | 11 | 2019 | 188 | 1.140 |
Why?
|
| Arthritis | 8 | 2024 | 659 | 1.060 |
Why?
|
| Treatment Outcome | 97 | 2023 | 63114 | 0.980 |
Why?
|
| Protein-Tyrosine Kinases | 6 | 2014 | 2455 | 0.960 |
Why?
|
| Gout | 5 | 2022 | 573 | 0.930 |
Why?
|
| Arthritis, Gouty | 1 | 2022 | 28 | 0.880 |
Why?
|
| Polyethylene Glycols | 7 | 2022 | 1182 | 0.870 |
Why?
|
| Registries | 23 | 2023 | 8089 | 0.840 |
Why?
|
| Azetidines | 3 | 2019 | 142 | 0.840 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 5 | 2014 | 2915 | 0.840 |
Why?
|
| Middle Aged | 194 | 2024 | 213383 | 0.820 |
Why?
|
| Lung Diseases, Interstitial | 8 | 2024 | 808 | 0.810 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 2021 | 20 | 0.800 |
Why?
|
| Polyglutamic Acid | 2 | 2019 | 44 | 0.800 |
Why?
|
| Immunoglobulin Fab Fragments | 3 | 2012 | 482 | 0.800 |
Why?
|
| Hand Joints | 3 | 2023 | 53 | 0.760 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2018 | 110 | 0.750 |
Why?
|
| Humans | 391 | 2024 | 744343 | 0.750 |
Why?
|
| Abortion, Criminal | 1 | 2019 | 2 | 0.740 |
Why?
|
| C-Reactive Protein | 18 | 2021 | 3778 | 0.700 |
Why?
|
| Female | 235 | 2024 | 380194 | 0.650 |
Why?
|
| Adult | 142 | 2024 | 214055 | 0.650 |
Why?
|
| Aged | 146 | 2024 | 163280 | 0.630 |
Why?
|
| Male | 210 | 2023 | 350118 | 0.630 |
Why?
|
| Remission Induction | 19 | 2021 | 2386 | 0.610 |
Why?
|
| Immunosuppressive Agents | 13 | 2020 | 4149 | 0.600 |
Why?
|
| Morpholines | 9 | 2018 | 571 | 0.590 |
Why?
|
| Arthritis, Psoriatic | 9 | 2019 | 215 | 0.580 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2017 | 61 | 0.580 |
Why?
|
| Aminopyridines | 9 | 2018 | 542 | 0.570 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2021 | 388 | 0.560 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 11 | 2020 | 2282 | 0.530 |
Why?
|
| Anaphylaxis | 1 | 2022 | 746 | 0.520 |
Why?
|
| Drug Substitution | 1 | 2018 | 281 | 0.520 |
Why?
|
| Lupus Erythematosus, Systemic | 12 | 2023 | 2104 | 0.520 |
Why?
|
| Dose-Response Relationship, Drug | 23 | 2018 | 10943 | 0.510 |
Why?
|
| Drug Administration Schedule | 18 | 2015 | 4933 | 0.500 |
Why?
|
| Pyrimidines | 12 | 2021 | 2942 | 0.500 |
Why?
|
| Disease Progression | 25 | 2023 | 13284 | 0.490 |
Why?
|
| Efficiency | 1 | 2017 | 462 | 0.480 |
Why?
|
| Pituitary Gland | 1 | 2017 | 665 | 0.480 |
Why?
|
| Sulfonamides | 3 | 2019 | 1938 | 0.470 |
Why?
|
| Immunocompromised Host | 5 | 2013 | 847 | 0.460 |
Why?
|
| Clinical Trials as Topic | 17 | 2019 | 7913 | 0.460 |
Why?
|
| Foot Joints | 1 | 2013 | 36 | 0.460 |
Why?
|
| Peptides, Cyclic | 8 | 2019 | 400 | 0.440 |
Why?
|
| Autoantibodies | 11 | 2017 | 2035 | 0.430 |
Why?
|
| Glucocorticoids | 8 | 2021 | 2107 | 0.430 |
Why?
|
| Immunologic Factors | 7 | 2011 | 1580 | 0.430 |
Why?
|
| Interleukin-6 | 5 | 2021 | 3200 | 0.410 |
Why?
|
| Drug Resistance | 4 | 2015 | 1609 | 0.410 |
Why?
|
| Quality of Life | 13 | 2024 | 12804 | 0.410 |
Why?
|
| Injections, Subcutaneous | 8 | 2017 | 666 | 0.400 |
Why?
|
| Immunoglobulins | 4 | 2018 | 881 | 0.390 |
Why?
|
| Radiography | 20 | 2023 | 7023 | 0.390 |
Why?
|
| Opportunistic Infections | 4 | 2015 | 389 | 0.380 |
Why?
|
| Health Status | 15 | 2021 | 4034 | 0.380 |
Why?
|
| Employment | 1 | 2017 | 1132 | 0.380 |
Why?
|
| Prodrugs | 2 | 2011 | 268 | 0.370 |
Why?
|
| Isoxazoles | 3 | 2000 | 216 | 0.360 |
Why?
|
| Fibromyalgia | 3 | 2022 | 388 | 0.360 |
Why?
|
| Uric Acid | 4 | 2022 | 766 | 0.360 |
Why?
|
| Dermatomyositis | 2 | 2017 | 224 | 0.350 |
Why?
|
| Health Resources | 1 | 2016 | 911 | 0.350 |
Why?
|
| Interleukin-17 | 4 | 2018 | 899 | 0.350 |
Why?
|
| Blood Sedimentation | 8 | 2017 | 231 | 0.340 |
Why?
|
| Lung Diseases | 9 | 2019 | 1886 | 0.340 |
Why?
|
| Gout Suppressants | 4 | 2022 | 166 | 0.330 |
Why?
|
| Fatigue | 7 | 2022 | 1531 | 0.330 |
Why?
|
| Disability Evaluation | 9 | 2016 | 1827 | 0.320 |
Why?
|
| Cyclosporins | 6 | 1991 | 220 | 0.320 |
Why?
|
| Polymyositis | 2 | 2006 | 75 | 0.310 |
Why?
|
| Joints | 10 | 2017 | 326 | 0.310 |
Why?
|
| Time Factors | 33 | 2021 | 40075 | 0.310 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2021 | 215 | 0.300 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2007 | 107 | 0.300 |
Why?
|
| Streptococcus pyogenes | 1 | 2009 | 289 | 0.290 |
Why?
|
| Cyclosporine | 3 | 1999 | 786 | 0.280 |
Why?
|
| Pyrroles | 3 | 2023 | 1146 | 0.280 |
Why?
|
| Pneumonia, Bacterial | 1 | 2009 | 316 | 0.270 |
Why?
|
| Pain Measurement | 7 | 2017 | 3420 | 0.270 |
Why?
|
| Prospective Studies | 36 | 2023 | 53288 | 0.260 |
Why?
|
| Aged, 80 and over | 31 | 2021 | 57776 | 0.260 |
Why?
|
| Cohort Studies | 40 | 2022 | 40561 | 0.250 |
Why?
|
| Streptococcal Infections | 1 | 2009 | 638 | 0.250 |
Why?
|
| Administration, Oral | 12 | 2018 | 3913 | 0.240 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2005 | 174 | 0.240 |
Why?
|
| Liver Cirrhosis | 5 | 2000 | 1863 | 0.240 |
Why?
|
| Venous Thromboembolism | 3 | 2021 | 1671 | 0.240 |
Why?
|
| Evidence-Based Medicine | 6 | 2013 | 3610 | 0.240 |
Why?
|
| Arthrography | 3 | 2014 | 149 | 0.230 |
Why?
|
| Sulfasalazine | 2 | 2004 | 79 | 0.230 |
Why?
|
| Hospitals, University | 1 | 2005 | 571 | 0.230 |
Why?
|
| Hydroxychloroquine | 6 | 2022 | 412 | 0.230 |
Why?
|
| Pandemics | 3 | 2022 | 8388 | 0.230 |
Why?
|
| Piperidines | 3 | 2021 | 1602 | 0.230 |
Why?
|
| Auranofin | 3 | 1993 | 15 | 0.230 |
Why?
|
| Prednisone | 12 | 2023 | 1574 | 0.230 |
Why?
|
| Withholding Treatment | 3 | 2013 | 599 | 0.230 |
Why?
|
| Arthralgia | 3 | 2022 | 456 | 0.220 |
Why?
|
| Chikungunya virus | 1 | 2022 | 50 | 0.210 |
Why?
|
| Still's Disease, Adult-Onset | 1 | 2002 | 19 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2017 | 5535 | 0.210 |
Why?
|
| Shock, Septic | 1 | 2009 | 775 | 0.210 |
Why?
|
| Prognosis | 20 | 2021 | 29063 | 0.210 |
Why?
|
| Adjuvants, Immunologic | 2 | 2003 | 1000 | 0.210 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2006 | 3772 | 0.210 |
Why?
|
| Leukotriene B4 | 3 | 1992 | 294 | 0.210 |
Why?
|
| Predictive Value of Tests | 12 | 2019 | 15076 | 0.200 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2023 | 9959 | 0.200 |
Why?
|
| Synovial Membrane | 5 | 2018 | 507 | 0.200 |
Why?
|
| Polymorphism, Single Nucleotide | 16 | 2019 | 15519 | 0.190 |
Why?
|
| Treatment Failure | 5 | 2015 | 2618 | 0.190 |
Why?
|
| Adolescent | 35 | 2021 | 85781 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 5 | 2019 | 2727 | 0.190 |
Why?
|
| Gene Expression Regulation | 6 | 2019 | 12072 | 0.190 |
Why?
|
| Collagenases | 2 | 2003 | 228 | 0.190 |
Why?
|
| Cholesterol, LDL | 3 | 2021 | 2356 | 0.180 |
Why?
|
| Young Adult | 13 | 2021 | 56430 | 0.180 |
Why?
|
| Purines | 3 | 2019 | 594 | 0.180 |
Why?
|
| Thrombocytopenia | 6 | 1994 | 1179 | 0.180 |
Why?
|
| Georgia | 1 | 2019 | 186 | 0.180 |
Why?
|
| Follow-Up Studies | 18 | 2019 | 39050 | 0.180 |
Why?
|
| Emphysema | 1 | 2022 | 247 | 0.170 |
Why?
|
| Herpesvirus 8, Human | 1 | 2021 | 258 | 0.170 |
Why?
|
| Research Design | 10 | 2019 | 5987 | 0.170 |
Why?
|
| Metalloendopeptidases | 2 | 2003 | 396 | 0.170 |
Why?
|
| Polysaccharides | 3 | 2012 | 1053 | 0.170 |
Why?
|
| Tuberculosis | 2 | 2009 | 1912 | 0.170 |
Why?
|
| Pulmonary Embolism | 3 | 2021 | 2376 | 0.170 |
Why?
|
| Kallikreins | 3 | 1989 | 258 | 0.170 |
Why?
|
| Pain | 8 | 2024 | 4986 | 0.170 |
Why?
|
| Canada | 2 | 2022 | 2065 | 0.170 |
Why?
|
| Liver | 9 | 2000 | 7474 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 5 | 2010 | 693 | 0.170 |
Why?
|
| Psychological Techniques | 1 | 2018 | 45 | 0.160 |
Why?
|
| Myositis | 2 | 2008 | 251 | 0.160 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 1 | 2018 | 33 | 0.160 |
Why?
|
| Monosomy | 2 | 1995 | 54 | 0.160 |
Why?
|
| Risk Assessment | 10 | 2021 | 23338 | 0.160 |
Why?
|
| Inflammation Mediators | 3 | 2016 | 1889 | 0.160 |
Why?
|
| Rhabdomyosarcoma | 3 | 1992 | 382 | 0.160 |
Why?
|
| Monitoring, Physiologic | 2 | 2014 | 1738 | 0.160 |
Why?
|
| Antigens, CD | 4 | 2019 | 4026 | 0.160 |
Why?
|
| Urate Oxidase | 3 | 2022 | 35 | 0.160 |
Why?
|
| Pneumococcal Vaccines | 2 | 2013 | 391 | 0.160 |
Why?
|
| Hyperplasia | 1 | 2021 | 1185 | 0.150 |
Why?
|
| Pharyngitis | 2 | 2016 | 215 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 12 | 2016 | 17446 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 1995 | 322 | 0.150 |
Why?
|
| Consensus | 4 | 2023 | 2959 | 0.150 |
Why?
|
| Prednisolone | 1 | 2018 | 334 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 5 | 2010 | 1790 | 0.150 |
Why?
|
| Synovial Fluid | 5 | 2017 | 394 | 0.150 |
Why?
|
| Lung | 7 | 2022 | 9856 | 0.150 |
Why?
|
| Linear Models | 6 | 2019 | 5952 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2013 | 11524 | 0.150 |
Why?
|
| Logistic Models | 8 | 2020 | 13408 | 0.150 |
Why?
|
| Pneumococcal Infections | 2 | 2013 | 497 | 0.150 |
Why?
|
| Herpesvirus 4, Human | 2 | 2013 | 1041 | 0.150 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2022 | 451 | 0.140 |
Why?
|
| Fenretinide | 1 | 1996 | 12 | 0.140 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2022 | 545 | 0.140 |
Why?
|
| Deoxyglucose | 1 | 1997 | 337 | 0.140 |
Why?
|
| Purpura, Thrombocytopenic | 2 | 1988 | 43 | 0.140 |
Why?
|
| Apyrase | 1 | 2019 | 364 | 0.140 |
Why?
|
| Risk Factors | 28 | 2022 | 72290 | 0.140 |
Why?
|
| Ancillary Services, Hospital | 1 | 1996 | 23 | 0.140 |
Why?
|
| Immunoassay | 2 | 2011 | 752 | 0.140 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2018 | 306 | 0.140 |
Why?
|
| Nasopharyngitis | 1 | 2015 | 10 | 0.140 |
Why?
|
| Troponin T | 1 | 2021 | 754 | 0.140 |
Why?
|
| Motor Activity | 4 | 2015 | 2714 | 0.140 |
Why?
|
| Spondylitis, Ankylosing | 4 | 2019 | 156 | 0.140 |
Why?
|
| Familial Mediterranean Fever | 1 | 1996 | 61 | 0.140 |
Why?
|
| Stomatitis, Aphthous | 1 | 1996 | 53 | 0.130 |
Why?
|
| Data Mining | 3 | 2021 | 537 | 0.130 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2021 | 1573 | 0.130 |
Why?
|
| Inflammation | 5 | 2021 | 10638 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2019 | 1855 | 0.130 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2018 | 1836 | 0.130 |
Why?
|
| Lymphadenitis | 1 | 1996 | 98 | 0.130 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 1995 | 648 | 0.130 |
Why?
|
| Anemia, Aplastic | 3 | 1991 | 226 | 0.130 |
Why?
|
| Patient Dropouts | 2 | 2013 | 421 | 0.130 |
Why?
|
| Tomography, Emission-Computed | 2 | 1997 | 1144 | 0.130 |
Why?
|
| Nurse's Role | 1 | 2017 | 209 | 0.130 |
Why?
|
| Autoimmune Diseases | 2 | 2022 | 2133 | 0.130 |
Why?
|
| Delphi Technique | 3 | 2020 | 778 | 0.130 |
Why?
|
| B-Cell Activating Factor | 1 | 2015 | 119 | 0.130 |
Why?
|
| Blood Transfusion, Intrauterine | 1 | 1994 | 26 | 0.130 |
Why?
|
| Dermatologic Agents | 1 | 2018 | 278 | 0.120 |
Why?
|
| Cardiovascular Diseases | 7 | 2022 | 15165 | 0.120 |
Why?
|
| Thymus Neoplasms | 1 | 1997 | 268 | 0.120 |
Why?
|
| Age Factors | 11 | 2019 | 18370 | 0.120 |
Why?
|
| Fees and Charges | 1 | 1996 | 195 | 0.120 |
Why?
|
| Genome-Wide Association Study | 6 | 2019 | 12261 | 0.120 |
Why?
|
| Tachyphylaxis | 1 | 1994 | 51 | 0.120 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2012 | 65 | 0.120 |
Why?
|
| Models, Economic | 1 | 2018 | 713 | 0.120 |
Why?
|
| Sjogren's Syndrome | 2 | 2014 | 233 | 0.120 |
Why?
|
| Antibodies, Neoplasm | 1 | 1995 | 286 | 0.120 |
Why?
|
| Biological Therapy | 1 | 2015 | 138 | 0.120 |
Why?
|
| Fluorine Radioisotopes | 1 | 1997 | 442 | 0.120 |
Why?
|
| Longitudinal Studies | 9 | 2017 | 13989 | 0.120 |
Why?
|
| Boston | 5 | 2021 | 9313 | 0.120 |
Why?
|
| Forecasting | 3 | 2018 | 2951 | 0.120 |
Why?
|
| Fanconi Anemia | 1 | 1996 | 319 | 0.120 |
Why?
|
| Peer Group | 1 | 2018 | 635 | 0.110 |
Why?
|
| Low Back Pain | 1 | 2022 | 956 | 0.110 |
Why?
|
| 14-3-3 Proteins | 1 | 2014 | 214 | 0.110 |
Why?
|
| Matrix Metalloproteinase 3 | 2 | 2008 | 134 | 0.110 |
Why?
|
| Misoprostol | 1 | 1994 | 95 | 0.110 |
Why?
|
| Sex Factors | 6 | 2019 | 10397 | 0.110 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2018 | 1838 | 0.110 |
Why?
|
| Cost Control | 1 | 1996 | 624 | 0.110 |
Why?
|
| Biomedical Research | 3 | 2019 | 3309 | 0.110 |
Why?
|
| Interleukin-1 | 4 | 2010 | 1263 | 0.110 |
Why?
|
| Pyrazoles | 3 | 2019 | 1972 | 0.110 |
Why?
|
| Neutropenia | 2 | 1995 | 895 | 0.110 |
Why?
|
| International Cooperation | 3 | 2015 | 1420 | 0.110 |
Why?
|
| Venous Thrombosis | 2 | 2019 | 1239 | 0.110 |
Why?
|
| Information Systems | 1 | 1995 | 410 | 0.110 |
Why?
|
| Chordoma | 1 | 1996 | 359 | 0.110 |
Why?
|
| Bone Density | 3 | 2018 | 3468 | 0.110 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 1992 | 94 | 0.110 |
Why?
|
| Cross-Sectional Studies | 12 | 2024 | 25043 | 0.110 |
Why?
|
| Hypertension | 7 | 2014 | 8480 | 0.110 |
Why?
|
| Antibodies | 5 | 2020 | 2460 | 0.100 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2013 | 162 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 1 | 2014 | 892 | 0.100 |
Why?
|
| Vasculitis | 4 | 1990 | 519 | 0.100 |
Why?
|
| Gilbert Disease | 1 | 2011 | 4 | 0.100 |
Why?
|
| Patient Education as Topic | 2 | 2020 | 2278 | 0.100 |
Why?
|
| Diarrhea | 2 | 2014 | 1348 | 0.100 |
Why?
|
| Tuberculin Test | 1 | 2012 | 214 | 0.100 |
Why?
|
| Databases as Topic | 2 | 2011 | 475 | 0.100 |
Why?
|
| Gold Sodium Thiomalate | 3 | 1999 | 10 | 0.100 |
Why?
|
| Leucovorin | 1 | 1993 | 628 | 0.100 |
Why?
|
| Patient Selection | 4 | 2017 | 4215 | 0.100 |
Why?
|
| Radius | 1 | 1994 | 422 | 0.100 |
Why?
|
| Platelet Transfusion | 1 | 1994 | 314 | 0.100 |
Why?
|
| Hyperbilirubinemia | 1 | 2011 | 77 | 0.100 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2017 | 986 | 0.100 |
Why?
|
| Muscular Diseases | 2 | 1989 | 556 | 0.100 |
Why?
|
| Hydroxyurea | 1 | 1992 | 290 | 0.100 |
Why?
|
| Peptide Fragments | 2 | 2021 | 5097 | 0.100 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2015 | 430 | 0.100 |
Why?
|
| Multivariate Analysis | 8 | 2019 | 12245 | 0.100 |
Why?
|
| Micrococcaceae | 1 | 1990 | 8 | 0.100 |
Why?
|
| Glucuronosyltransferase | 1 | 2011 | 128 | 0.100 |
Why?
|
| Antibodies, Heterophile | 1 | 2011 | 126 | 0.100 |
Why?
|
| Liver Failure | 1 | 1993 | 241 | 0.100 |
Why?
|
| Exercise | 2 | 2017 | 5615 | 0.090 |
Why?
|
| Galactose | 1 | 2012 | 306 | 0.090 |
Why?
|
| Editorial Policies | 1 | 2015 | 451 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 1411 | 0.090 |
Why?
|
| Lipoproteins, HDL | 1 | 2015 | 638 | 0.090 |
Why?
|
| Self Report | 3 | 2017 | 3558 | 0.090 |
Why?
|
| Phospholipases A2, Secretory | 1 | 2010 | 31 | 0.090 |
Why?
|
| Infectious Mononucleosis | 1 | 1991 | 131 | 0.090 |
Why?
|
| B-Lymphocytes | 3 | 2017 | 4665 | 0.090 |
Why?
|
| Bacterial Infections | 2 | 2007 | 1401 | 0.090 |
Why?
|
| Liver Diseases | 5 | 1996 | 1253 | 0.090 |
Why?
|
| Incidence | 9 | 2021 | 20947 | 0.090 |
Why?
|
| Societies, Medical | 4 | 2021 | 3743 | 0.090 |
Why?
|
| Professional Practice | 1 | 2012 | 326 | 0.090 |
Why?
|
| Drug Discovery | 1 | 2018 | 1058 | 0.090 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1990 | 58 | 0.090 |
Why?
|
| Algorithms | 5 | 2013 | 13881 | 0.090 |
Why?
|
| Herpes Zoster | 2 | 2016 | 264 | 0.090 |
Why?
|
| Neutrophils | 4 | 2002 | 3719 | 0.090 |
Why?
|
| Lymphatic Irradiation | 1 | 1990 | 103 | 0.090 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1994 | 652 | 0.090 |
Why?
|
| Latent Tuberculosis | 1 | 2012 | 225 | 0.090 |
Why?
|
| Nucleotide Deaminases | 1 | 2009 | 11 | 0.090 |
Why?
|
| Hydroxymethyl and Formyl Transferases | 1 | 2009 | 17 | 0.090 |
Why?
|
| Bilirubin | 1 | 2011 | 425 | 0.090 |
Why?
|
| Pregnadienes | 1 | 1988 | 24 | 0.090 |
Why?
|
| Adiposity | 1 | 2019 | 1807 | 0.090 |
Why?
|
| Forced Expiratory Volume | 1 | 2014 | 1743 | 0.090 |
Why?
|
| Eicosanoids | 1 | 1991 | 279 | 0.080 |
Why?
|
| Hodgkin Disease | 1 | 1997 | 1415 | 0.080 |
Why?
|
| HLA-DR Antigens | 4 | 2018 | 645 | 0.080 |
Why?
|
| Danazol | 1 | 1988 | 42 | 0.080 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 1989 | 2232 | 0.080 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 1989 | 86 | 0.080 |
Why?
|
| Metacarpal Bones | 1 | 2009 | 73 | 0.080 |
Why?
|
| Neuroblastoma | 3 | 1988 | 1226 | 0.080 |
Why?
|
| Fetal Diseases | 1 | 1994 | 903 | 0.080 |
Why?
|
| Polyradiculoneuropathy | 1 | 1988 | 64 | 0.080 |
Why?
|
| RANK Ligand | 1 | 2010 | 326 | 0.080 |
Why?
|
| Blood Cell Count | 1 | 1989 | 403 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 2886 | 0.080 |
Why?
|
| Chronic Disease | 9 | 2023 | 9146 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2017 | 6365 | 0.080 |
Why?
|
| Antigen-Antibody Complex | 1 | 2010 | 517 | 0.080 |
Why?
|
| Aortitis | 1 | 1989 | 74 | 0.080 |
Why?
|
| Patient Compliance | 2 | 2014 | 2684 | 0.080 |
Why?
|
| Interleukin-1alpha | 1 | 2008 | 84 | 0.080 |
Why?
|
| Cell-Derived Microparticles | 1 | 2010 | 168 | 0.080 |
Why?
|
| Myocardium | 1 | 2021 | 4776 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2021 | 2788 | 0.080 |
Why?
|
| Proportional Hazards Models | 7 | 2019 | 12354 | 0.080 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2009 | 224 | 0.080 |
Why?
|
| HLA-DR4 Antigen | 1 | 2007 | 28 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 697 | 0.080 |
Why?
|
| Fatal Outcome | 4 | 2009 | 1850 | 0.080 |
Why?
|
| Medicare | 5 | 2022 | 6566 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2022 | 4034 | 0.080 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 570 | 0.070 |
Why?
|
| Acyltransferases | 1 | 1989 | 294 | 0.070 |
Why?
|
| Prenatal Diagnosis | 1 | 1994 | 1236 | 0.070 |
Why?
|
| Glucosamine | 1 | 1987 | 132 | 0.070 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2012 | 639 | 0.070 |
Why?
|
| Blood | 1 | 1989 | 598 | 0.070 |
Why?
|
| Apolipoprotein A-I | 2 | 2021 | 281 | 0.070 |
Why?
|
| Infarction | 1 | 1988 | 244 | 0.070 |
Why?
|
| Placebos | 2 | 2006 | 1676 | 0.070 |
Why?
|
| Collagen | 3 | 2018 | 2689 | 0.070 |
Why?
|
| North America | 1 | 2010 | 1249 | 0.070 |
Why?
|
| Database Management Systems | 1 | 2008 | 270 | 0.070 |
Why?
|
| Case-Control Studies | 11 | 2020 | 21746 | 0.070 |
Why?
|
| Leukopenia | 1 | 1987 | 212 | 0.070 |
Why?
|
| Reproducibility of Results | 7 | 2019 | 19905 | 0.070 |
Why?
|
| Apolipoproteins B | 2 | 2021 | 374 | 0.070 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 1991 | 233 | 0.070 |
Why?
|
| Medical Records | 3 | 2007 | 1413 | 0.070 |
Why?
|
| Polycythemia | 1 | 1987 | 126 | 0.070 |
Why?
|
| Alternative Splicing | 1 | 2012 | 1117 | 0.070 |
Why?
|
| Diclofenac | 1 | 2006 | 71 | 0.070 |
Why?
|
| Serum | 1 | 2007 | 214 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2007 | 380 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2018 | 4386 | 0.070 |
Why?
|
| Chromosomes, Human | 1 | 2008 | 457 | 0.070 |
Why?
|
| Glomerulonephritis | 1 | 1988 | 372 | 0.070 |
Why?
|
| T-Lymphocytes | 5 | 2012 | 10180 | 0.070 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1987 | 110 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2013 | 6538 | 0.070 |
Why?
|
| Cross-Over Studies | 3 | 2015 | 2029 | 0.070 |
Why?
|
| Candidiasis | 2 | 2006 | 366 | 0.070 |
Why?
|
| Aspartate Aminotransferases | 2 | 1999 | 418 | 0.070 |
Why?
|
| ROC Curve | 4 | 2015 | 3527 | 0.070 |
Why?
|
| Kidney | 5 | 1994 | 7186 | 0.070 |
Why?
|
| Advisory Committees | 2 | 2020 | 775 | 0.070 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1991 | 501 | 0.070 |
Why?
|
| Office Visits | 1 | 2010 | 598 | 0.070 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2009 | 386 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2018 | 3002 | 0.070 |
Why?
|
| Comorbidity | 4 | 2015 | 10388 | 0.070 |
Why?
|
| Sacrococcygeal Region | 1 | 1985 | 52 | 0.070 |
Why?
|
| Child, Preschool | 23 | 2009 | 41006 | 0.070 |
Why?
|
| Sickness Impact Profile | 1 | 2007 | 302 | 0.070 |
Why?
|
| Drug Interactions | 4 | 2012 | 1460 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 2861 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 4 | 2016 | 7279 | 0.070 |
Why?
|
| Alleles | 5 | 2013 | 6933 | 0.070 |
Why?
|
| Bone Marrow | 6 | 1990 | 2948 | 0.070 |
Why?
|
| Myocardial Infarction | 4 | 2022 | 11727 | 0.070 |
Why?
|
| Azathioprine | 2 | 2006 | 353 | 0.070 |
Why?
|
| Endpoint Determination | 1 | 2008 | 601 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2016 | 2266 | 0.060 |
Why?
|
| Bone Diseases | 1 | 2009 | 416 | 0.060 |
Why?
|
| United States | 13 | 2022 | 69872 | 0.060 |
Why?
|
| Neoplasms | 9 | 2010 | 21683 | 0.060 |
Why?
|
| Multienzyme Complexes | 1 | 2009 | 686 | 0.060 |
Why?
|
| Teratoma | 2 | 1985 | 395 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2017 | 3188 | 0.060 |
Why?
|
| Haplotypes | 2 | 2008 | 2779 | 0.060 |
Why?
|
| Frontal Lobe | 1 | 1992 | 1406 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2013 | 1161 | 0.060 |
Why?
|
| Databases, Factual | 3 | 2020 | 7729 | 0.060 |
Why?
|
| Sensitivity and Specificity | 5 | 2014 | 14722 | 0.060 |
Why?
|
| Antigens, CD19 | 2 | 2006 | 380 | 0.060 |
Why?
|
| Paraplegia | 1 | 1985 | 168 | 0.060 |
Why?
|
| Ambulatory Care | 1 | 1996 | 2708 | 0.060 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 1986 | 131 | 0.060 |
Why?
|
| RNA | 1 | 2015 | 2749 | 0.060 |
Why?
|
| Gene Dosage | 1 | 2009 | 1252 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 320 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2015 | 3870 | 0.060 |
Why?
|
| Mass Screening | 2 | 2012 | 5255 | 0.060 |
Why?
|
| Quality of Health Care | 4 | 2014 | 4371 | 0.060 |
Why?
|
| Congresses as Topic | 2 | 2019 | 764 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 1995 | 3523 | 0.060 |
Why?
|
| Alcohol Drinking | 1 | 2017 | 3966 | 0.060 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 1432 | 0.060 |
Why?
|
| Biopsy | 8 | 2000 | 6756 | 0.060 |
Why?
|
| Regression Analysis | 4 | 2019 | 6459 | 0.060 |
Why?
|
| Psoriasis | 4 | 2003 | 898 | 0.060 |
Why?
|
| Hemoglobins | 2 | 2023 | 1534 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2018 | 4217 | 0.060 |
Why?
|
| Receptors, Chemokine | 2 | 2017 | 669 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2009 | 3206 | 0.060 |
Why?
|
| Respiratory Function Tests | 3 | 2019 | 1616 | 0.060 |
Why?
|
| Point-of-Care Systems | 1 | 2013 | 1177 | 0.060 |
Why?
|
| Sulfones | 1 | 2006 | 437 | 0.060 |
Why?
|
| Hemangioendothelioma | 1 | 1984 | 121 | 0.060 |
Why?
|
| Drug Evaluation | 1 | 2005 | 647 | 0.060 |
Why?
|
| Genetic Variation | 2 | 2009 | 6544 | 0.060 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1984 | 188 | 0.060 |
Why?
|
| Tetralogy of Fallot | 1 | 2009 | 623 | 0.060 |
Why?
|
| Creatine Kinase | 1 | 2006 | 694 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2007 | 1572 | 0.060 |
Why?
|
| Tripterygium | 1 | 2023 | 16 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 3 | 2006 | 1677 | 0.060 |
Why?
|
| Ovarian Neoplasms | 3 | 1997 | 4838 | 0.060 |
Why?
|
| Insurance Claim Review | 1 | 2008 | 720 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2013 | 1378 | 0.060 |
Why?
|
| Melanoma | 1 | 2022 | 5510 | 0.060 |
Why?
|
| Skin | 1 | 2017 | 4364 | 0.060 |
Why?
|
| Glucose-6-Phosphate Isomerase | 1 | 2003 | 52 | 0.060 |
Why?
|
| Area Under Curve | 3 | 2015 | 1654 | 0.060 |
Why?
|
| Clinical Protocols | 1 | 1989 | 1462 | 0.060 |
Why?
|
| Repressor Proteins | 2 | 2017 | 3023 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 2 | 1996 | 2734 | 0.060 |
Why?
|
| Ganglioneuroma | 1 | 1983 | 57 | 0.060 |
Why?
|
| Range of Motion, Articular | 2 | 2007 | 1578 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2010 | 13033 | 0.060 |
Why?
|
| Herpes Simplex | 1 | 2006 | 470 | 0.060 |
Why?
|
| Medication Adherence | 1 | 2014 | 2063 | 0.060 |
Why?
|
| Pennsylvania | 3 | 2011 | 613 | 0.060 |
Why?
|
| Pulmonary Fibrosis | 2 | 1992 | 530 | 0.060 |
Why?
|
| Muscle Weakness | 1 | 2006 | 413 | 0.060 |
Why?
|
| Hypotension | 1 | 2009 | 884 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2012 | 1978 | 0.050 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2003 | 141 | 0.050 |
Why?
|
| Enzyme Precursors | 1 | 2003 | 176 | 0.050 |
Why?
|
| Dysgerminoma | 1 | 1982 | 65 | 0.050 |
Why?
|
| Leukemia, Lymphoid | 1 | 1983 | 315 | 0.050 |
Why?
|
| Crohn Disease | 3 | 2009 | 2303 | 0.050 |
Why?
|
| Interleukin-1beta | 1 | 2008 | 972 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 5686 | 0.050 |
Why?
|
| Finger Joint | 1 | 2023 | 108 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2010 | 2740 | 0.050 |
Why?
|
| Antibody Formation | 2 | 2023 | 1402 | 0.050 |
Why?
|
| Hypothyroidism | 1 | 1987 | 658 | 0.050 |
Why?
|
| Indoles | 1 | 2011 | 1839 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2005 | 421 | 0.050 |
Why?
|
| Single-Blind Method | 2 | 2015 | 1590 | 0.050 |
Why?
|
| Sarcoma | 2 | 1991 | 1897 | 0.050 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2017 | 2425 | 0.050 |
Why?
|
| Principal Component Analysis | 2 | 2021 | 940 | 0.050 |
Why?
|
| Dianhydrogalactitol | 1 | 1981 | 3 | 0.050 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 2020 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3133 | 0.050 |
Why?
|
| Confidence Intervals | 3 | 2014 | 2971 | 0.050 |
Why?
|
| Leukemia | 1 | 1990 | 1511 | 0.050 |
Why?
|
| Sugar Alcohols | 1 | 1981 | 18 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
| Liver Function Tests | 2 | 1994 | 528 | 0.050 |
Why?
|
| Brain Neoplasms | 5 | 1997 | 8863 | 0.050 |
Why?
|
| Program Development | 1 | 2008 | 1316 | 0.050 |
Why?
|
| Needs Assessment | 2 | 2019 | 1147 | 0.050 |
Why?
|
| Monocytes | 5 | 1992 | 2596 | 0.050 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1991 | 1363 | 0.050 |
Why?
|
| Pregnancy | 4 | 2019 | 29144 | 0.050 |
Why?
|
| Caffeine | 1 | 2006 | 699 | 0.050 |
Why?
|
| Abdominal Neoplasms | 1 | 1983 | 292 | 0.050 |
Why?
|
| Synovitis | 1 | 1983 | 209 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 4 | 1994 | 1170 | 0.050 |
Why?
|
| Chemokines | 3 | 2015 | 970 | 0.050 |
Why?
|
| Wrist Joint | 1 | 2023 | 256 | 0.050 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1984 | 340 | 0.050 |
Why?
|
| Splenectomy | 1 | 1982 | 395 | 0.050 |
Why?
|
| Sialoglycoproteins | 1 | 2002 | 318 | 0.050 |
Why?
|
| Osteoarthritis | 2 | 2006 | 1036 | 0.050 |
Why?
|
| Diet | 2 | 2017 | 7939 | 0.050 |
Why?
|
| Child | 21 | 1997 | 77709 | 0.050 |
Why?
|
| Pilot Projects | 4 | 2003 | 8324 | 0.050 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2003 | 659 | 0.050 |
Why?
|
| Antineoplastic Agents | 4 | 1996 | 13695 | 0.050 |
Why?
|
| Infant | 15 | 1995 | 35136 | 0.050 |
Why?
|
| Retrospective Studies | 10 | 2024 | 77449 | 0.050 |
Why?
|
| Combined Modality Therapy | 5 | 2003 | 8642 | 0.050 |
Why?
|
| Radionuclide Imaging | 2 | 1982 | 2031 | 0.050 |
Why?
|
| Cisplatin | 1 | 1987 | 1662 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2010 | 2575 | 0.050 |
Why?
|
| Respiratory Insufficiency | 1 | 2009 | 1199 | 0.050 |
Why?
|
| Genotype | 6 | 2011 | 12951 | 0.050 |
Why?
|
| Densitometry | 1 | 1980 | 156 | 0.050 |
Why?
|
| Antibodies, Viral | 2 | 2023 | 3176 | 0.050 |
Why?
|
| Diagnosis, Differential | 5 | 2009 | 12959 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2013 | 2214 | 0.050 |
Why?
|
| Mycoplasma Infections | 1 | 1980 | 118 | 0.050 |
Why?
|
| Asthma | 2 | 2009 | 6011 | 0.050 |
Why?
|
| Complementary Therapies | 1 | 2004 | 486 | 0.040 |
Why?
|
| Syndrome | 3 | 1996 | 3251 | 0.040 |
Why?
|
| Penicillamine | 1 | 1999 | 59 | 0.040 |
Why?
|
| Physician's Role | 1 | 2007 | 943 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 3798 | 0.040 |
Why?
|
| False Positive Reactions | 3 | 1997 | 981 | 0.040 |
Why?
|
| Chemotaxis, Leukocyte | 3 | 1992 | 675 | 0.040 |
Why?
|
| Tuberous Sclerosis | 1 | 1987 | 1029 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2005 | 1183 | 0.040 |
Why?
|
| Cholesterol | 2 | 2021 | 2917 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2010 | 2508 | 0.040 |
Why?
|
| Brazil | 1 | 2023 | 1270 | 0.040 |
Why?
|
| Hematologic Diseases | 3 | 1989 | 498 | 0.040 |
Why?
|
| Life Style | 3 | 2020 | 3835 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 5867 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 357 | 0.040 |
Why?
|
| Family Health | 2 | 1996 | 1282 | 0.040 |
Why?
|
| Proteomics | 2 | 2022 | 3638 | 0.040 |
Why?
|
| Kidney Diseases | 4 | 1994 | 2149 | 0.040 |
Why?
|
| Reference Values | 3 | 2014 | 4982 | 0.040 |
Why?
|
| Cytokines | 2 | 2011 | 7322 | 0.040 |
Why?
|
| Injections, Intravenous | 2 | 2003 | 1420 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 551 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2013 | 5102 | 0.040 |
Why?
|
| Infant, Premature, Diseases | 1 | 1984 | 706 | 0.040 |
Why?
|
| Recombinant Proteins | 4 | 2003 | 6622 | 0.040 |
Why?
|
| Telomere | 1 | 2024 | 910 | 0.040 |
Why?
|
| Central Nervous System Stimulants | 1 | 2006 | 1148 | 0.040 |
Why?
|
| Phenotype | 6 | 2021 | 16365 | 0.040 |
Why?
|
| Morbidity | 2 | 2015 | 1769 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2013 | 3749 | 0.040 |
Why?
|
| Macrophage-Activating Factors | 1 | 2017 | 21 | 0.040 |
Why?
|
| Random Allocation | 3 | 1988 | 2429 | 0.040 |
Why?
|
| Prevalence | 4 | 2020 | 15226 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2019 | 539 | 0.040 |
Why?
|
| Interleukin-23 | 1 | 2018 | 193 | 0.040 |
Why?
|
| Chemokine CXCL13 | 1 | 2017 | 54 | 0.040 |
Why?
|
| Risk | 6 | 2008 | 9687 | 0.040 |
Why?
|
| Receptors, CXCR5 | 1 | 2017 | 92 | 0.040 |
Why?
|
| Gold | 3 | 1990 | 484 | 0.040 |
Why?
|
| Recurrence | 3 | 2013 | 8340 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2013 | 2016 | 0.040 |
Why?
|
| Immunologic Memory | 3 | 2018 | 1348 | 0.040 |
Why?
|
| Janus Kinase 1 | 1 | 2016 | 104 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 1999 | 592 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2020 | 20129 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2013 | 4468 | 0.040 |
Why?
|
| Cysts | 1 | 1982 | 678 | 0.040 |
Why?
|
| Encephalitis | 1 | 1980 | 423 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2017 | 193 | 0.030 |
Why?
|
| Sepsis | 1 | 2010 | 2593 | 0.030 |
Why?
|
| Cecal Diseases | 1 | 1996 | 51 | 0.030 |
Why?
|
| Colitis | 1 | 1984 | 1170 | 0.030 |
Why?
|
| Nausea | 1 | 1999 | 673 | 0.030 |
Why?
|
| Doxorubicin | 3 | 1996 | 2234 | 0.030 |
Why?
|
| Chemokines, CXC | 1 | 1998 | 422 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2005 | 2418 | 0.030 |
Why?
|
| Expert Testimony | 1 | 2018 | 356 | 0.030 |
Why?
|
| Ifosfamide | 1 | 1996 | 228 | 0.030 |
Why?
|
| Janus Kinases | 1 | 2017 | 244 | 0.030 |
Why?
|
| Aurothioglucose | 1 | 1995 | 11 | 0.030 |
Why?
|
| Receptors, CCR5 | 1 | 1998 | 497 | 0.030 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2015 | 49 | 0.030 |
Why?
|
| Diabetes Mellitus | 2 | 2002 | 5751 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1995 | 370 | 0.030 |
Why?
|
| Models, Biological | 1 | 2012 | 9583 | 0.030 |
Why?
|
| Postmenopause | 2 | 2018 | 2461 | 0.030 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2015 | 58 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 3 | 1993 | 2765 | 0.030 |
Why?
|
| Odds Ratio | 3 | 2017 | 9849 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 610 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2015 | 68 | 0.030 |
Why?
|
| Karyotyping | 2 | 1995 | 1243 | 0.030 |
Why?
|
| Cordocentesis | 1 | 1994 | 8 | 0.030 |
Why?
|
| Ceftriaxone | 1 | 1996 | 168 | 0.030 |
Why?
|
| Delivery of Health Care | 3 | 2020 | 5319 | 0.030 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 1997 | 241 | 0.030 |
Why?
|
| Allopurinol | 1 | 1996 | 191 | 0.030 |
Why?
|
| Ulcer | 1 | 1996 | 209 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2018 | 1369 | 0.030 |
Why?
|
| Propensity Score | 1 | 2021 | 1781 | 0.030 |
Why?
|
| Research | 2 | 2019 | 1999 | 0.030 |
Why?
|
| Carcinoma, Endometrioid | 1 | 1997 | 271 | 0.030 |
Why?
|
| Infant, Newborn | 10 | 1990 | 25625 | 0.030 |
Why?
|
| Down Syndrome | 2 | 1989 | 880 | 0.030 |
Why?
|
| Cartilage | 1 | 2018 | 818 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2018 | 1588 | 0.030 |
Why?
|
| HLA-DR3 Antigen | 1 | 2014 | 34 | 0.030 |
Why?
|
| Thyroid Function Tests | 1 | 1995 | 286 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 924 | 0.030 |
Why?
|
| Intestinal Perforation | 1 | 1996 | 253 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2007 | 3528 | 0.030 |
Why?
|
| Arachidonate 5-Lipoxygenase | 2 | 1992 | 144 | 0.030 |
Why?
|
| Salicylates | 2 | 1986 | 126 | 0.030 |
Why?
|
| Drug Tolerance | 1 | 1995 | 376 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 426 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2021 | 2715 | 0.030 |
Why?
|
| Hemolysis | 1 | 1996 | 420 | 0.030 |
Why?
|
| Kidney Transplantation | 1 | 1989 | 4251 | 0.030 |
Why?
|
| Leukemic Infiltration | 1 | 1993 | 48 | 0.030 |
Why?
|
| Diet Surveys | 1 | 2017 | 1173 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2018 | 1057 | 0.030 |
Why?
|
| Software | 1 | 2007 | 4443 | 0.030 |
Why?
|
| Health Surveys | 2 | 2017 | 4037 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 1518 | 0.030 |
Why?
|
| Amyloidosis | 1 | 2000 | 795 | 0.030 |
Why?
|
| Triglycerides | 1 | 2021 | 2454 | 0.030 |
Why?
|
| Health Priorities | 1 | 2016 | 380 | 0.030 |
Why?
|
| Thalidomide | 1 | 2018 | 890 | 0.030 |
Why?
|
| Anemia, Sideroblastic | 1 | 1994 | 101 | 0.030 |
Why?
|
| Platelet Activating Factor | 2 | 1990 | 149 | 0.030 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 2 | 2006 | 297 | 0.030 |
Why?
|
| Bronchiectasis | 1 | 1994 | 128 | 0.030 |
Why?
|
| Epidemiologic Methods | 2 | 2009 | 1364 | 0.030 |
Why?
|
| Genes, ras | 1 | 1995 | 690 | 0.030 |
Why?
|
| Radiographic Image Enhancement | 1 | 2018 | 885 | 0.030 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 1993 | 1519 | 0.030 |
Why?
|
| Liver Neoplasms | 3 | 1985 | 4253 | 0.030 |
Why?
|
| Glycoproteins | 2 | 1995 | 2263 | 0.030 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2014 | 236 | 0.030 |
Why?
|
| Massachusetts | 1 | 2005 | 8663 | 0.030 |
Why?
|
| Infection Control | 1 | 2020 | 966 | 0.030 |
Why?
|
| Carotid Artery, Common | 1 | 2013 | 183 | 0.030 |
Why?
|
| Hip Joint | 2 | 2009 | 1002 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2014 | 434 | 0.030 |
Why?
|
| Hemochromatosis | 1 | 1994 | 184 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1987 | 3143 | 0.030 |
Why?
|
| Peer Review, Research | 1 | 2015 | 329 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 1999 | 2373 | 0.030 |
Why?
|
| Interleukins | 1 | 2017 | 791 | 0.030 |
Why?
|
| Iris | 1 | 1993 | 239 | 0.030 |
Why?
|
| Health Behavior | 2 | 2014 | 2636 | 0.030 |
Why?
|
| Iron | 2 | 1994 | 1774 | 0.030 |
Why?
|
| Socioeconomic Factors | 3 | 2021 | 7785 | 0.030 |
Why?
|
| Aging | 1 | 1991 | 8664 | 0.030 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1994 | 732 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1990 | 9239 | 0.020 |
Why?
|
| Vaginal Smears | 1 | 2014 | 511 | 0.020 |
Why?
|
| Thromboxane B2 | 1 | 1991 | 152 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2019 | 2019 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 1956 | 0.020 |
Why?
|
| Leptin | 1 | 2019 | 1599 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 1987 | 4262 | 0.020 |
Why?
|
| Phospholipases | 1 | 1990 | 72 | 0.020 |
Why?
|
| Perception | 1 | 2017 | 1198 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2017 | 3923 | 0.020 |
Why?
|
| Calcimycin | 1 | 1990 | 222 | 0.020 |
Why?
|
| SOXD Transcription Factors | 1 | 2010 | 47 | 0.020 |
Why?
|
| Vaccination | 1 | 2023 | 3278 | 0.020 |
Why?
|
| Hospitalization | 2 | 2008 | 10262 | 0.020 |
Why?
|
| Receptors, Collagen | 1 | 2010 | 26 | 0.020 |
Why?
|
| Headache | 2 | 2016 | 1226 | 0.020 |
Why?
|
| Dexamethasone | 2 | 1996 | 1951 | 0.020 |
Why?
|
| Pancytopenia | 2 | 1981 | 104 | 0.020 |
Why?
|
| Heart Failure | 2 | 2019 | 10900 | 0.020 |
Why?
|
| Renal Circulation | 1 | 1991 | 333 | 0.020 |
Why?
|
| Genomics | 1 | 2006 | 5720 | 0.020 |
Why?
|
| Creatinine | 3 | 1991 | 1919 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1982 | 2214 | 0.020 |
Why?
|
| Genome, Human | 3 | 2008 | 4420 | 0.020 |
Why?
|
| Thyroid Hormones | 2 | 1995 | 390 | 0.020 |
Why?
|
| Steroids | 1 | 2015 | 930 | 0.020 |
Why?
|
| Life Tables | 1 | 1990 | 370 | 0.020 |
Why?
|
| Lymphocyte Activation | 3 | 2012 | 5524 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2016 | 1814 | 0.020 |
Why?
|
| Extracellular Matrix | 2 | 2010 | 1741 | 0.020 |
Why?
|
| Luciferases | 1 | 2012 | 733 | 0.020 |
Why?
|
| Arachidonic Acids | 1 | 1990 | 299 | 0.020 |
Why?
|
| Disease Management | 1 | 2020 | 2459 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 35421 | 0.020 |
Why?
|
| Animals | 7 | 2024 | 168757 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2018 | 2488 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2016 | 1151 | 0.020 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 1990 | 226 | 0.020 |
Why?
|
| Rheumatoid Nodule | 1 | 1989 | 15 | 0.020 |
Why?
|
| Growth Substances | 1 | 1992 | 784 | 0.020 |
Why?
|
| Kinins | 1 | 1989 | 22 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1993 | 805 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 905 | 0.020 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 1998 | 4266 | 0.020 |
Why?
|
| Congenital Abnormalities | 1 | 1994 | 707 | 0.020 |
Why?
|
| Research Personnel | 1 | 2014 | 573 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 1997 | 1061 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2013 | 616 | 0.020 |
Why?
|
| Child Abuse | 1 | 1998 | 1030 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2014 | 681 | 0.020 |
Why?
|
| Probenecid | 1 | 1989 | 76 | 0.020 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 2010 | 293 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 1990 | 434 | 0.020 |
Why?
|
| Mycobacterium kansasii | 1 | 2008 | 11 | 0.020 |
Why?
|
| Mycobacterium avium | 1 | 2008 | 28 | 0.020 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 9438 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2012 | 976 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 1683 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2014 | 1997 | 0.020 |
Why?
|
| Antacids | 1 | 1989 | 99 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 1995 | 956 | 0.020 |
Why?
|
| Nervous System Malformations | 1 | 1990 | 247 | 0.020 |
Why?
|
| Thrombocythemia, Essential | 1 | 1989 | 105 | 0.020 |
Why?
|
| Cyclophosphamide | 4 | 1993 | 2242 | 0.020 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2014 | 624 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2018 | 5078 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2009 | 323 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2012 | 2050 | 0.020 |
Why?
|
| Dermatology | 1 | 2018 | 872 | 0.020 |
Why?
|
| Self Care | 1 | 2013 | 786 | 0.020 |
Why?
|
| Phenytoin | 1 | 1989 | 197 | 0.020 |
Why?
|
| Mortality | 1 | 2020 | 2864 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 2 | 2009 | 936 | 0.020 |
Why?
|
| Churg-Strauss Syndrome | 1 | 1988 | 70 | 0.020 |
Why?
|
| Drug Industry | 1 | 2014 | 746 | 0.020 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 1988 | 30 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1994 | 1681 | 0.020 |
Why?
|
| Fetal Hemoglobin | 1 | 1990 | 341 | 0.020 |
Why?
|
| Rocky Mountain Spotted Fever | 1 | 1987 | 19 | 0.020 |
Why?
|
| Giant Cell Arteritis | 2 | 1982 | 292 | 0.020 |
Why?
|
| Glycoside Hydrolases | 1 | 2007 | 133 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2018 | 2576 | 0.020 |
Why?
|
| Tablets | 1 | 1988 | 145 | 0.020 |
Why?
|
| Ribose | 1 | 1987 | 68 | 0.020 |
Why?
|
| Histamine H2 Antagonists | 1 | 1989 | 165 | 0.020 |
Why?
|
| Aorta | 2 | 2013 | 2061 | 0.020 |
Why?
|
| DNA Primers | 1 | 2012 | 2892 | 0.020 |
Why?
|
| Hydrops Fetalis | 1 | 1988 | 107 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2011 | 841 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 2759 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2012 | 1730 | 0.020 |
Why?
|
| Family | 1 | 1998 | 3147 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2009 | 658 | 0.020 |
Why?
|
| Smoking | 1 | 2024 | 8987 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 1995 | 1988 | 0.020 |
Why?
|
| Complementarity Determining Regions | 1 | 2007 | 149 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2013 | 1442 | 0.020 |
Why?
|
| Mutation | 2 | 2011 | 29786 | 0.020 |
Why?
|
| Hand | 2 | 2009 | 884 | 0.020 |
Why?
|
| Homozygote | 1 | 2011 | 1785 | 0.020 |
Why?
|
| Erythropoiesis | 1 | 1990 | 705 | 0.020 |
Why?
|
| Vincristine | 2 | 1993 | 1039 | 0.020 |
Why?
|
| Ultrasonography, Prenatal | 1 | 1994 | 1695 | 0.020 |
Why?
|
| Coccyx | 1 | 1985 | 12 | 0.020 |
Why?
|
| Food, Fortified | 1 | 1987 | 191 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 2 | 2010 | 6386 | 0.020 |
Why?
|
| Fasciitis | 1 | 1986 | 65 | 0.020 |
Why?
|
| Half-Life | 2 | 2003 | 661 | 0.020 |
Why?
|
| Platelet Activation | 1 | 2010 | 673 | 0.020 |
Why?
|
| British Columbia | 1 | 2006 | 244 | 0.020 |
Why?
|
| Cerebral Arterial Diseases | 1 | 1986 | 82 | 0.020 |
Why?
|
| Aorta, Abdominal | 1 | 1989 | 646 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2013 | 1547 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 5391 | 0.020 |
Why?
|
| Myelodysplastic Syndromes | 1 | 1995 | 1352 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1995 | 2942 | 0.020 |
Why?
|
| Lithium | 1 | 1989 | 601 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1990 | 689 | 0.020 |
Why?
|
| Babesiosis | 1 | 1986 | 92 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2015 | 2925 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2008 | 1681 | 0.020 |
Why?
|
| Erythrocytes | 2 | 2012 | 2455 | 0.020 |
Why?
|
| Databases, Nucleic Acid | 1 | 2006 | 211 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2007 | 741 | 0.020 |
Why?
|
| Educational Status | 1 | 2013 | 2540 | 0.020 |
Why?
|
| Pharmacoepidemiology | 1 | 2008 | 323 | 0.020 |
Why?
|
| Mothers | 1 | 1996 | 2165 | 0.020 |
Why?
|
| Leukocytes | 2 | 1998 | 2043 | 0.020 |
Why?
|
| Thrombosis | 1 | 2019 | 2968 | 0.020 |
Why?
|
| Paraneoplastic Syndromes | 1 | 1986 | 151 | 0.020 |
Why?
|
| Blood Coagulation Factors | 1 | 1987 | 355 | 0.020 |
Why?
|
| Stroke | 3 | 2019 | 9981 | 0.020 |
Why?
|
| Respiratory Sounds | 1 | 2009 | 696 | 0.020 |
Why?
|
| Drug Eruptions | 1 | 1988 | 297 | 0.020 |
Why?
|
| Bone Marrow Diseases | 1 | 1987 | 231 | 0.020 |
Why?
|
| HLA Antigens | 2 | 1988 | 1381 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2002 | 5137 | 0.020 |
Why?
|
| Cell Movement | 1 | 2017 | 5217 | 0.020 |
Why?
|
| Laminectomy | 1 | 1985 | 234 | 0.020 |
Why?
|
| Thoracic Neoplasms | 1 | 1987 | 268 | 0.020 |
Why?
|
| Blood Coagulation Disorders | 1 | 1987 | 337 | 0.020 |
Why?
|
| Technetium | 2 | 1983 | 334 | 0.020 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 1984 | 97 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2007 | 927 | 0.020 |
Why?
|
| False Negative Reactions | 2 | 1983 | 588 | 0.010 |
Why?
|
| Immunoglobulin gamma-Chains | 1 | 2003 | 33 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2012 | 5179 | 0.010 |
Why?
|
| Muscles | 1 | 1989 | 1614 | 0.010 |
Why?
|
| Electromyography | 1 | 1989 | 1379 | 0.010 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2008 | 875 | 0.010 |
Why?
|
| Fish Oils | 1 | 1987 | 470 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 1257 | 0.010 |
Why?
|
| Age of Onset | 1 | 2010 | 3271 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 2009 | 1725 | 0.010 |
Why?
|
| Europe | 1 | 2010 | 3339 | 0.010 |
Why?
|
| Japan | 1 | 1988 | 1360 | 0.010 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 1831 | 0.010 |
Why?
|
| Thigh | 1 | 1984 | 247 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2014 | 3494 | 0.010 |
Why?
|
| Colon | 2 | 1997 | 1772 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 1991 | 2170 | 0.010 |
Why?
|
| Mental Health | 1 | 2017 | 3019 | 0.010 |
Why?
|
| Organotechnetium Compounds | 1 | 1983 | 137 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 1985 | 1475 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 1990 | 20822 | 0.010 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 1985 | 317 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2008 | 2421 | 0.010 |
Why?
|
| Outpatients | 1 | 2010 | 1486 | 0.010 |
Why?
|
| Endothelium | 1 | 1985 | 778 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2018 | 10481 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 1989 | 1082 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2012 | 2564 | 0.010 |
Why?
|
| Chromosome Mapping | 2 | 2008 | 4740 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1982 | 318 | 0.010 |
Why?
|
| Infertility, Male | 1 | 1985 | 409 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 3508 | 0.010 |
Why?
|
| Intestine, Small | 1 | 1988 | 1241 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 1985 | 930 | 0.010 |
Why?
|
| Polymyalgia Rheumatica | 1 | 1982 | 54 | 0.010 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 1982 | 44 | 0.010 |
Why?
|
| Rheumatic Fever | 1 | 1982 | 71 | 0.010 |
Why?
|
| Ependymoma | 2 | 1983 | 334 | 0.010 |
Why?
|
| Spine | 1 | 2009 | 1144 | 0.010 |
Why?
|
| Plasmapheresis | 1 | 1982 | 211 | 0.010 |
Why?
|
| Blood Donors | 1 | 1984 | 355 | 0.010 |
Why?
|
| Cryoglobulinemia | 1 | 1982 | 87 | 0.010 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 2703 | 0.010 |
Why?
|
| Bursitis | 1 | 1982 | 83 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2008 | 1904 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 1990 | 2258 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1996 | 3336 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2019 | 12720 | 0.010 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 1981 | 66 | 0.010 |
Why?
|
| Adenocarcinoma | 2 | 1997 | 6364 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 1504 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2006 | 2297 | 0.010 |
Why?
|
| Latex Fixation Tests | 1 | 1980 | 32 | 0.010 |
Why?
|
| Observer Variation | 1 | 2007 | 2593 | 0.010 |
Why?
|
| Splenic Neoplasms | 1 | 1981 | 100 | 0.010 |
Why?
|
| Mycoplasma pneumoniae | 1 | 1980 | 43 | 0.010 |
Why?
|
| Epitopes | 1 | 2007 | 2571 | 0.010 |
Why?
|
| Sulfur | 1 | 1981 | 166 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 2009 | 1848 | 0.010 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 1982 | 214 | 0.010 |
Why?
|
| Gallium Radioisotopes | 1 | 1981 | 178 | 0.010 |
Why?
|
| Age Distribution | 1 | 2006 | 2902 | 0.010 |
Why?
|
| Gene Expression | 1 | 2013 | 7799 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2006 | 2634 | 0.010 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2006 | 1205 | 0.010 |
Why?
|
| Myofibrils | 1 | 2000 | 146 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2017 | 11483 | 0.010 |
Why?
|
| Dacarbazine | 1 | 1982 | 566 | 0.010 |
Why?
|
| Urogenital Neoplasms | 1 | 1981 | 137 | 0.010 |
Why?
|
| Infertility, Female | 1 | 1985 | 787 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2010 | 4161 | 0.010 |
Why?
|
| Choroid Plexus | 1 | 1982 | 231 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 1989 | 2046 | 0.010 |
Why?
|
| Cerebrospinal Fluid | 1 | 1982 | 534 | 0.010 |
Why?
|
| Autoantigens | 1 | 2003 | 892 | 0.010 |
Why?
|
| Protein Binding | 1 | 2011 | 9386 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1990 | 3461 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 2274 | 0.010 |
Why?
|
| Arthritis, Infectious | 1 | 1982 | 367 | 0.010 |
Why?
|
| Abdomen | 1 | 1984 | 1118 | 0.010 |
Why?
|
| Scattering, Radiation | 1 | 1980 | 498 | 0.010 |
Why?
|
| Scleroderma, Systemic | 1 | 1982 | 323 | 0.010 |
Why?
|
| Pneumothorax | 1 | 1982 | 379 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2021 | 23403 | 0.010 |
Why?
|
| Arm | 1 | 1981 | 589 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2009 | 3768 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1982 | 1619 | 0.010 |
Why?
|
| Sarcoidosis | 1 | 2003 | 506 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 6234 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 1997 | 6773 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1982 | 13102 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 9734 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2002 | 1880 | 0.010 |
Why?
|
| Fractures, Bone | 1 | 2009 | 1947 | 0.010 |
Why?
|
| Safety | 1 | 2002 | 1186 | 0.010 |
Why?
|
| Skin Diseases | 1 | 1985 | 1065 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2009 | 3821 | 0.010 |
Why?
|
| Receptors, CXCR3 | 1 | 1998 | 237 | 0.010 |
Why?
|
| Chemokine CXCL10 | 1 | 1998 | 304 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1995 | 7181 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1989 | 10252 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 1986 | 1786 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1984 | 3616 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 1989 | 2872 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 2010 | 19229 | 0.010 |
Why?
|
| Lipids | 1 | 1987 | 3305 | 0.010 |
Why?
|
| Knee Joint | 2 | 1982 | 1680 | 0.010 |
Why?
|
| Lasers | 1 | 1980 | 952 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1995 | 335 | 0.010 |
Why?
|
| Mice | 3 | 2010 | 81183 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 16689 | 0.010 |
Why?
|
| Poverty | 1 | 2007 | 2660 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2010 | 14557 | 0.010 |
Why?
|
| Femur | 1 | 1981 | 1297 | 0.010 |
Why?
|
| Chemotaxis | 1 | 1998 | 607 | 0.010 |
Why?
|
| Interview, Psychological | 1 | 1998 | 812 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 1981 | 1301 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1995 | 318 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 1995 | 199 | 0.010 |
Why?
|
| Pseudomonas | 1 | 1994 | 117 | 0.010 |
Why?
|
| Haemophilus influenzae | 1 | 1994 | 171 | 0.010 |
Why?
|
| Thioguanine | 1 | 1993 | 46 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 1995 | 299 | 0.010 |
Why?
|
| B-Lymphocyte Subsets | 1 | 1995 | 246 | 0.010 |
Why?
|
| Anticoagulants | 1 | 1989 | 4599 | 0.010 |
Why?
|
| Daunorubicin | 1 | 1993 | 158 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 1986 | 2538 | 0.010 |
Why?
|
| HLA-DQ Antigens | 1 | 1993 | 210 | 0.010 |
Why?
|
| Zymosan | 1 | 1992 | 124 | 0.010 |
Why?
|
| Lymphopenia | 1 | 1995 | 285 | 0.010 |
Why?
|
| Whole-Body Irradiation | 1 | 1993 | 449 | 0.010 |
Why?
|
| Clone Cells | 1 | 1995 | 1692 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 21827 | 0.010 |
Why?
|
| Sputum | 1 | 1994 | 476 | 0.010 |
Why?
|
| Asparaginase | 1 | 1993 | 236 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1993 | 708 | 0.010 |
Why?
|
| Etoposide | 1 | 1993 | 641 | 0.010 |
Why?
|
| Knee Prosthesis | 1 | 1995 | 425 | 0.010 |
Why?
|
| Cytarabine | 1 | 1993 | 692 | 0.010 |
Why?
|
| Sulfamethoxazole | 1 | 1990 | 53 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 18029 | 0.010 |
Why?
|
| Dandy-Walker Syndrome | 1 | 1990 | 43 | 0.010 |
Why?
|
| Trimethoprim | 1 | 1990 | 91 | 0.010 |
Why?
|
| Cranial Irradiation | 1 | 1993 | 401 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1990 | 356 | 0.010 |
Why?
|
| Glioma | 2 | 1983 | 3401 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1998 | 6314 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1998 | 2617 | 0.010 |
Why?
|
| Acute Disease | 2 | 1996 | 7149 | 0.010 |
Why?
|
| Bone Marrow Examination | 1 | 1989 | 157 | 0.010 |
Why?
|
| Pedigree | 1 | 1997 | 4644 | 0.010 |
Why?
|
| Colonoscopy | 1 | 1997 | 1367 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1988 | 191 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 1981 | 2529 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1993 | 1842 | 0.000 |
Why?
|
| Partial Thromboplastin Time | 1 | 1987 | 206 | 0.000 |
Why?
|
| Population Surveillance | 1 | 1997 | 2616 | 0.000 |
Why?
|
| Reflex Sympathetic Dystrophy | 1 | 1986 | 58 | 0.000 |
Why?
|
| Salvage Therapy | 1 | 1993 | 1275 | 0.000 |
Why?
|
| Blood Coagulation Tests | 1 | 1987 | 263 | 0.000 |
Why?
|
| Salicylic Acid | 1 | 1986 | 56 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1995 | 6171 | 0.000 |
Why?
|
| Social Support | 1 | 1996 | 2118 | 0.000 |
Why?
|
| Staphylococcus aureus | 1 | 1994 | 1451 | 0.000 |
Why?
|
| Metabolic Clearance Rate | 1 | 1986 | 380 | 0.000 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 1986 | 104 | 0.000 |
Why?
|
| Thromboplastin | 1 | 1987 | 291 | 0.000 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1996 | 6038 | 0.000 |
Why?
|
| Transplantation, Autologous | 1 | 1990 | 2124 | 0.000 |
Why?
|
| Plasminogen Activators | 1 | 1985 | 209 | 0.000 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 1986 | 134 | 0.000 |
Why?
|
| Muscle, Skeletal | 1 | 2000 | 4931 | 0.000 |
Why?
|
| Chromosomes, Human, 6-12 and X | 1 | 1984 | 80 | 0.000 |
Why?
|
| Hematocrit | 1 | 1986 | 636 | 0.000 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1985 | 821 | 0.000 |
Why?
|
| Spleen | 1 | 1990 | 2362 | 0.000 |
Why?
|
| Haploidy | 1 | 1984 | 136 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1985 | 2186 | 0.000 |
Why?
|
| New York | 1 | 1986 | 886 | 0.000 |
Why?
|
| Elastin | 1 | 1985 | 308 | 0.000 |
Why?
|
| Cerebral Arteries | 1 | 1986 | 494 | 0.000 |
Why?
|
| Lymphatic System | 1 | 1985 | 253 | 0.000 |
Why?
|
| Sugar Acids | 1 | 1983 | 24 | 0.000 |
Why?
|
| Diatrizoate Meglumine | 1 | 1983 | 83 | 0.000 |
Why?
|
| Leukemia, Myeloid | 1 | 1986 | 707 | 0.000 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 1983 | 68 | 0.000 |
Why?
|
| Abnormalities, Multiple | 1 | 1990 | 1416 | 0.000 |
Why?
|
| Pentetic Acid | 1 | 1983 | 213 | 0.000 |
Why?
|
| Bursa, Synovial | 1 | 1982 | 24 | 0.000 |
Why?
|
| HLA-B Antigens | 1 | 1984 | 353 | 0.000 |
Why?
|
| Multiple Myeloma | 1 | 2000 | 5181 | 0.000 |
Why?
|
| Base Sequence | 1 | 1993 | 12797 | 0.000 |
Why?
|
| Retinal Artery | 1 | 1982 | 111 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 1995 | 11366 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1993 | 13815 | 0.000 |
Why?
|
| Complement System Proteins | 1 | 1984 | 795 | 0.000 |
Why?
|
| Arthrodesis | 1 | 1982 | 189 | 0.000 |
Why?
|
| Temporal Arteries | 1 | 1982 | 128 | 0.000 |
Why?
|
| Cerebral Angiography | 1 | 1986 | 1285 | 0.000 |
Why?
|
| Anemia | 1 | 1989 | 1506 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1993 | 18111 | 0.000 |
Why?
|
| Cattle | 1 | 1985 | 3922 | 0.000 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1985 | 1504 | 0.000 |
Why?
|
| Astrocytoma | 1 | 1983 | 790 | 0.000 |
Why?
|
| Kinetics | 1 | 1986 | 6473 | 0.000 |
Why?
|
| Radiotherapy | 1 | 1985 | 1533 | 0.000 |
Why?
|
| Cell Division | 1 | 1985 | 4568 | 0.000 |
Why?
|
| Medulloblastoma | 1 | 1983 | 683 | 0.000 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1982 | 793 | 0.000 |
Why?
|
| Gene Frequency | 1 | 1984 | 3588 | 0.000 |
Why?
|
| Nervous System Diseases | 1 | 1986 | 1622 | 0.000 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1982 | 1381 | 0.000 |
Why?
|
| Brain | 1 | 1982 | 26385 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1988 | 8554 | 0.000 |
Why?
|
| Electroencephalography | 1 | 1986 | 6150 | 0.000 |
Why?
|
| Rats | 1 | 1985 | 24260 | 0.000 |
Why?
|
| Pancreatic Neoplasms | 1 | 1986 | 5256 | 0.000 |
Why?
|
| Mental Disorders | 1 | 1986 | 6600 | 0.000 |
Why?
|